Human Biobank in San Francisco Bay Area (California, USA)
Cureline, Inc., was established in 2003 in the San Francisco Bay area (California, USA) to address the needs of biomedical researchers in high-quality medically and technical-sound, legally and ethically procured human biospecimens (HBS). A group of translational medicine experts from SUGEN (Pharmacia, Pfizer) started Cureline as a small laboratory specializing in complex scientific protocols. Since then we have expanded Cureline Clinical Network to over 150 clinical partners in 20 countries and successfully conducted 4,000+ projects, including participation in the major international programs for genomic and proteomic analyses of human tumors: The Cancer Genome Atlas (TCGA) and Clinical Proteomics Tumor Analysis Consortium (CPTAC) under the leadership of the National Cancer Institute (NIH).
To order specimens directly - please visit Cureline Online Biorepository.
Cureline Biobanking Concepts
Cureline HBS collection protocols have been developed in compliance with the international and local regulations and guidelines and approved by local IRBs and Ethical Committees. All specimens are properly consented and will arrival to your laboratory with de-identified clinical data fit into a project-specific Clinical Report Form (CRF).
Cureline Biorepository contains 50,000 – 100,000 specimens and our goal is making sure that they reach qualified laboratories ASAP. We work together with our clinical partners and clients to assure the shortest route from clinic to research bench with donated HBS and back to patients with novel medicines and new tests.
Our protocols accommodate the quality requirements of most research methods currently used in the drug discovery and development process. Cureline works under the guidelines of the College of American Pathologists (CAP) biorepository certification program and guarantees the quality of all provided human materials and services.
If you do not see here what you are looking for – please Contact us to discuss your questions.
